0753 GMT - AstraZeneca is continuing to deliver strong growth but uncertainty over U.S. tariffs remain, Quilter Cheviot's Sheena Berry writes. Its second-quarter performance was primarily driven by 18% growth in its oncology portfolio and AstraZeneca is showing no sign of slowing down research and development spending, Berry adds. Meanwhile, the Anglo-Swedish pharmaceutical giant should want to stay on the right side of President Trump as much as possible given the treat posed by tariffs to its growing U.S. revenue stream, Berry writes. Shares rise 0.5% to 10,840 pence. (adam.whittaker@wsj.com)
(END) Dow Jones Newswires
July 29, 2025 03:53 ET (07:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.